Rankings
▼
Calendar
ALGS Q3 2019 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
ALGS
Aligos Therapeutics, Inc.
$45M
Q3 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$15M
Net Income
-$14M
EPS (Diluted)
$-0.64
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$13M
Free Cash Flow
-$14M
Stock-Based Comp.
$151,000
← FY 2019
All Quarters
Q4 2019 →